Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Dollar Steady as Markets Await U.S. Inflation Data 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
U.S. Stock Futures Flat Ahead of July CPI Data 
Australia Housing Crisis Deepens as Worker Shortages Delay Homebuilding 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Gold Price Holds Near $4,400 as Hormuz Risks and CPI Drive Markets 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Gold Prices Rise as Fed Rate Hike Bets Ease 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
